AI Verdict
LIMNW has stronger fundamentals based on our AI analysis.
LIMNW vs LILAB Fundamental Comparison
| Metric | LIMNW | LILAB |
|---|---|---|
| Revenue | N/A | $4.4B |
| Net Income | $-10.2M | $-611.2M |
| Net Margin | N/A | -13.8% |
| ROE | N/A | -110.0% |
| ROA | -1,990.4% | -5.0% |
| Current Ratio | 0.05x | 1.14x |
| Debt/Equity | N/A | 14.89x |
| EPS | $-0.43 | $-3.06 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
LIMNW vs LILAB: Frequently Asked Questions
Is LIMNW or LILAB a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), LIMNW has stronger fundamentals. LIMNW is rated STRONG SELL (95% confidence) while LILAB is rated STRONG SELL (88% confidence). This is not investment advice.
How does LIMNW compare to LILAB fundamentally?
Liminatus Pharma, Inc. has ROE of N/A vs Liberty Latin America Ltd.'s -110.0%. Net margins are N/A vs -13.8% respectively.
Which stock pays higher dividends, LIMNW or LILAB?
LIMNW has a dividend yield of N/A or no dividend while LILAB has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in LIMNW or LILAB for long term?
For long-term investing, consider that LIMNW has STRONG SELL rating with 95% confidence, while LILAB has STRONG SELL rating with 88% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about LIMNW vs LILAB?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For LIMNW vs LILAB, the AI consensus favors LIMNW based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.